13-Mar-2026
Canaccord Genuity Remains a Buy on Seres Therapeutics (MCRB)
TipRanks (Fri, 13-Mar 7:59 AM ET)
Seres Therapeutics GAAP EPS of $0.64, revenue of $0.78M
Seeking Alpha News (Thu, 12-Mar 3:38 PM ET)
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline
TipRanks (Thu, 12-Mar 8:08 AM ET)
Globe Newswire (Thu, 12-Mar 7:00 AM ET)
Globe Newswire (Mon, 2-Mar 4:05 PM ET)
Seres Extends Cash Runway and Refocuses Pipeline on Inflammatory and Immune Diseases
Market Chameleon (Thu, 12-Feb 3:23 AM ET)
Globe Newswire (Thu, 12-Feb 7:00 AM ET)
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Seres Therapeutics trades on the NASDAQ stock market under the symbol MCRB.
As of March 13, 2026, MCRB stock price declined to $8.63 with 37,399 million shares trading.
MCRB has a beta of 1.96, meaning it tends to be more sensitive to market movements. MCRB has a correlation of 0.11 to the broad based SPY ETF.
MCRB has a market cap of $78.07 million. This is considered a Micro Cap stock.
Last quarter Seres Therapeutics reported $438,000 in Revenue and -$1.76 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.16.
In the last 3 years, MCRB traded as high as $137.40 and as low as $6.53.
The top ETF exchange traded funds that MCRB belongs to (by Net Assets): VTI, VXF, AVUV, SCHA, IWC.
MCRB has underperformed the market in the last year with a return of -37.8%, while the SPY ETF gained +19.8%. In the last 3 month period, MCRB fell short of the market, returning -49.1%, while SPY returned -2.6%. However, in the most recent 2 weeks MCRB has outperformed the stock market by returning -2.8%, while SPY returned -3.9%.
MCRB support price is $8.41 and resistance is $9.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCRB shares will trade within this expected range on the day.